Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-11-02
DOI
10.3389/fphar.2022.973366
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy
- (2021) Johanna C. Arroyave-Ospina et al. Antioxidants
- Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
- (2021) Atef Al Attar et al. Expert Review of Clinical Pharmacology
- Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice
- (2021) Junxiao Li et al. PHYTOTHERAPY RESEARCH
- Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
- (2021) Anand V. Kulkarni et al. Clinics and Research in Hepatology and Gastroenterology
- Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
- (2021) Frank Tacke et al. Annals of Translational Medicine
- Bicyclol ameliorates nonalcoholic fatty liver disease in mice via inhibiting MAPKs and NF-κB signaling pathways
- (2021) Weixin Zhao et al. BIOMEDICINE & PHARMACOTHERAPY
- Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- The effects of co‐administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial
- (2021) Mohammad Bagher Majnooni et al. PHYTOTHERAPY RESEARCH
- Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis
- (2021) Rifaat Safadi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
- (2021) V. Ratziu et al. NATURE MEDICINE
- The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver
- (2021) Daniela Gabbia et al. Frontiers in Nutrition
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Combined Effect of Omega-3 Fatty Acids and Phytosterol Ester on alleviating Hepatic Steatosis in NAFLD Subjects: A Double-blind Placebo-controlled Clinical Trial
- (2020) Lihua Song et al. BRITISH JOURNAL OF NUTRITION
- Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease
- (2020) Eleonora Scorletti et al. GASTROENTEROLOGY
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
- (2020) Jiyu Zhou et al. Nature Communications
- Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis
- (2020) Björn Carlsson et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice
- (2020) Erhan Sahin et al. JOURNAL OF FOOD BIOCHEMISTRY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
- (2020) Charlotte J Green et al. BMJ Open Diabetes Research & Care
- Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis
- (2020) Kristoffer Kjærgaard et al. JOURNAL OF HEPATOLOGY
- Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats
- (2020) Ryuichi Noguchi et al. Molecular Medicine Reports
- The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
- (2020) Divya P. Kumar et al. Scientific Reports
- Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers
- (2020) John Climax et al. Journal of the American Heart Association
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- Antioxidant activity of Hydroxytyrosol and Vitamin E reduces systemic inflammation in children with paediatric NAFLD
- (2020) Antonella Mosca et al. DIGESTIVE AND LIVER DISEASE
- Systematic review with meta‐analysis: The effect of vitamin E supplementation in adult patients with non‐alcoholic fatty liver disease
- (2020) Andreas Vadarlis et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Combination of luteolin and lycopene effectively protect against the “two-hit” in NAFLD through Sirt1/AMPK signal pathway
- (2020) Yaoxiang Zhu et al. LIFE SCIENCES
- Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
- (2020) Stefan Traussnigg et al. WIENER KLINISCHE WOCHENSCHRIFT
- Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis
- (2020) Maren C. Podszun et al. Redox Biology
- Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
- (2020) Longying Jiang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice
- (2020) Fahimeh Zamani-Garmsiri et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
- (2020) Hongjiao Xu et al. Nature Communications
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis
- (2020) Georgios Kalopitas et al. NUTRITION
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetics of Nonalcoholic Fatty Liver Disease: a 2018 Update.
- (2019) Luca VC Valenti et al. CURRENT PHARMACEUTICAL DESIGN
- The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection
- (2019) Hai Hu et al. Frontiers in Immunology
- Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial
- (2019) Helen Parker et al. Nutrients
- Genetics of Nonalcoholic Fatty Liver Disease: From Pathogenesis to Therapeutics
- (2019) Silvia Sookoian et al. SEMINARS IN LIVER DISEASE
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?
- (2019) Tien S Dong et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review
- (2019) Vahid Soleimani et al. PHYTOTHERAPY RESEARCH
- Diagnosis and management of non-alcoholic fatty liver disease
- (2019) Erica Jennison et al. POSTGRADUATE MEDICAL JOURNAL
- Microbial metabolites in non-alcoholic fatty liver disease
- (2019) Da Zhou et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease
- (2019) Sol Jae Lee et al. Expert Review of Gastroenterology & Hepatology
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
- (2019) Andrew A. Li et al. Gut and Liver
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
- (2019) Jonathan D. Roth et al. Scientific Reports
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
- (2019) Victor J. Navarro et al. PLoS One
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice
- (2019) Pnina Fishman et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α–FGF21 axis in mice
- (2019) Ahmed Aljohani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients
- (2019) Alessandro Federico et al. Oxidative Medicine and Cellular Longevity
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
- (2019) Quentin M. Anstee et al. Contemporary Clinical Trials
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- (2019) Naga Chalasani et al. GASTROENTEROLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
- (2019) Michael K. Badman et al. Clinical Pharmacology in Drug Development
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis
- (2018) Donghee Kim et al. Clinical Gastroenterology and Hepatology
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
- (2018) Frank Tacke EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
- (2018) José Del Campo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Endoplasmic Reticulum stress signaling and the pathogenesis of Non-Alcoholic Fatty Liver Disease
- (2018) Cynthia Lebeaupin et al. JOURNAL OF HEPATOLOGY
- Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial
- (2018) Farnush Bakhshimoghaddam et al. JOURNAL OF NUTRITION
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Mechanisms of NAFLD development and therapeutic strategies
- (2018) Scott L. Friedman et al. NATURE MEDICINE
- LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice
- (2018) Cong Thuc Le et al. PLoS One
- A giant amphipathic helix from a perilipin that is adapted for coating lipid droplets
- (2018) Alenka Čopič et al. Nature Communications
- Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
- (2018) Ying-Bin Hu et al. Drug Design Development and Therapy
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis
- (2018) Huilin Tang et al. Cancer Medicine
- Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial
- (2018) Antigoni Manousopoulou et al. CLINICAL NUTRITION
- Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
- (2018) Rui Li et al. International Journal of Biological Sciences
- Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
- (2018) Jan Oscarsson et al. Journal of Clinical Lipidology
- Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor
- (2018) Renchao Dong et al. PHYTOMEDICINE
- Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
- (2018) Stephen A. Harrison et al. PLoS One
- The nuclear receptor superfamily: A structural perspective
- (2018) Emily R. Weikum et al. PROTEIN SCIENCE
- Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial
- (2018) Paola Portillo-Sanchez et al. Journal of Diabetes
- Role of vitamin E in nonalcoholic fatty liver disease
- (2018) Mayumi Nagashimada et al. IUBMB LIFE
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study
- (2018) Nazarii Kobyliak et al. MINERVA MEDICA
- Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
- (2018) Bancha Satirapoj et al. PLoS One
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Mutant PNPLA3 I148M protein as pharmacological target for liver disease
- (2017) Luca Valenti et al. HEPATOLOGY
- Liver inflammation and fibrosis
- (2017) Yukinori Koyama et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting hepatic macrophages to treat liver diseases
- (2017) Frank Tacke JOURNAL OF HEPATOLOGY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Altenusin, a Nonsteroidal Microbial Metabolite, Attenuates Nonalcoholic Fatty Liver Disease by Activating the Farnesoid X Receptor
- (2017) Zhihui Zheng et al. MOLECULAR PHARMACOLOGY
- A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
- (2017) Müjdat Zeybel et al. MOLECULAR THERAPY
- Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- (2017) Alessandro Federico et al. MOLECULES
- Multimaterial Decomposition Algorithm for the Quantification of Liver Fat Content by Using Fast-Kilovolt-Peak Switching Dual-Energy CT: Clinical Evaluation
- (2017) Tomoko Hyodo et al. RADIOLOGY
- Silymarin: An option to treat non-alcoholic fatty liver disease
- (2017) Carmela Colica et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy
- (2017) Junli Ma et al. Nutrients
- Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
- (2017) Hani Jouihan et al. Molecular Metabolism
- Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
- (2017) Tobias Puengel et al. PLoS One
- Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
- (2016) S. A. Harrison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies
- (2016) Cynthia Ju et al. Cellular & Molecular Immunology
- Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
- (2016) Dharmesh H. Kaswala et al. DIGESTIVE DISEASES AND SCIENCES
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
- (2016) Kento Imajo et al. GASTROENTEROLOGY
- Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol
- (2016) Kuan-Ta Wu et al. Journal of Clinical Lipidology
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy
- (2016) Gil Ohana et al. Molecular Medicine Reports
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Fat: Mechanisms of Protein Localization to Lipid Droplets
- (2016) Nora Kory et al. TRENDS IN CELL BIOLOGY
- Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
- (2016) Eric Lefebvre et al. PLoS One
- Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH)
- (2015) Aastha Jindal et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility
- (2015) Ioannis Koutsounas et al. Expert Opinion on Drug Metabolism & Toxicology
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Arginase 2 deficiency results in spontaneous steatohepatitis: A novel link between innate immune activation and hepatic de novo lipogenesis
- (2015) Laura A. Navarro et al. JOURNAL OF HEPATOLOGY
- Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
- (2015) Curtis K. Argo et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients
- (2015) Fernando Bril et al. LIVER INTERNATIONAL
- A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease
- (2015) Pei-Wen Zhang et al. MEDICINE
- Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis
- (2015) Yun-Hua Li et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
- (2014) Tannaz Eslamparast et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Pathological Features of Fatty Liver Disease
- (2014) Matthew M. Yeh et al. GASTROENTEROLOGY
- CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis
- (2014) Josef Ehling et al. GUT
- Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease
- (2014) Forouzan Faghihzadeh et al. NUTRITION RESEARCH
- Perilipin discerns chronic from acute hepatocellular steatosis
- (2013) Lena Maria Pawella et al. JOURNAL OF HEPATOLOGY
- Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis
- (2013) A. Wehr et al. JOURNAL OF IMMUNOLOGY
- Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
- (2011) Christer Baeck et al. GUT
- The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population
- (2011) Chih-Wen Wang et al. LIVER INTERNATIONAL
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites
- (2010) Brent A. Neuschwander-Tetri HEPATOLOGY
- CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver
- (2010) S. Cohen et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Liraglutide
- (2010) Daniel J. Drucker et al. NATURE REVIEWS DRUG DISCOVERY
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2009) Amy G. Shah et al. Clinical Gastroenterology and Hepatology
- The A 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-κB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats
- (2008) A. Ochaion et al. BIOCHEMICAL PHARMACOLOGY
- Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
- (2008) Fergus McTaggart et al. CARDIOVASCULAR DRUGS AND THERAPY
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction
- (2008) Thomas D. Giles et al. JOURNAL OF CARDIAC FAILURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now